- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Axel Bex, MD, PhD | Authors
‘Absolutely Important’ to Develop Better Ways to Predict Kidney Cancer Recurrence, Says Expert
December 28, 2022
Future research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.
Why European Experts Cautiously Recommend Pembrolizumab to Treat High-Risk Kidney Cancer Following Surgery
December 27, 2022
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Urologists Should Make Patients With Metastatic Kidney Cancer Aware that not All Trials Have Positive Results, Says Expert
December 25, 2022
Patients with kidney cancer should be made aware of trials that have not read out positively in the adjuvant setting, according to an expert from the Royal Free London NHS Foundation Trust.
Adjuvant Treatment of Kidney Cancer Remains an Uncertainty, Says Expert
December 20, 2022
“Much more research” is needed to advance the adjuvant treatment of patients with kidney cancer, according to an expert from the Royal Free London NHS Foundation Trust.